A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome
NCT00796003
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
39
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndrome
Interventions
DRUG:
JNJ-30979754 15 mg/m2
DRUG:
JNJ-30979754 20 mg/m2
Sponsor
Janssen Pharmaceutical K.K.